首页 > 最新文献

Cancer Management and Research最新文献

英文 中文
Predicting the Recurrence of Ovarian Cancer Based on Machine Learning. 基于机器学习预测卵巢癌复发
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S482837
Lining Zhou, Hong Hong, Fuying Chu, Xiang Chen, Chenlu Wang

Background: Recurrence is the main factor for poor prognosis in ovarian cancer, but few prognostic biomarkers were reported. In this study, we used machine learning methods based on multiple biomarkers to develop a specific prediction model for the recurrence of ovarian cancer.

Methods: A total of 277 ovarian cancer patients were enrolled in this study and randomly classified into training and testing cohorts. The prediction information was obtained through 47 clinical parameters using six supervised clustering machine learning algorithms, including K-Nearest Neighbor (K-NN), Decision Tree (DT), Random Forest (RF), Adaptive Boosting (AdaBoost), Gradient Boosting Machine (GBM), and Extreme Gradient Boosting (XGBoost).

Results: In predicting the recurrence of ovarian cancer, machine learning algorithm was superior to conventional logistic regression analysis. In this study, XGBoost showed the best performance in predicting the recurrence of ovarian cancer, with an accuracy of 0.95. In addition, neoadjuvant chemotherapy, Monocyte ratio (MONO%), Hematocrit (HCT), Prealbumin (PAB), Aspartate aminotransferase (AST), and carbohydrate antigen 125 (CA125) are the most important biomarkers to predict the recurrence of ovarian cancer.

Conclusion: The machine learning techniques can achieve a more accurate assessment of the recurrence of ovarian cancer, which can help clinicians make decisions, and develop personalized treatment strategies.

背景:复发是卵巢癌预后不良的主要因素,但很少有关于预后生物标志物的报道。在这项研究中,我们使用基于多种生物标志物的机器学习方法,建立了一个特定的卵巢癌复发预测模型:方法:本研究共纳入了 277 名卵巢癌患者,并将其随机分为训练组和测试组。利用六种监督聚类机器学习算法,包括K-近邻(K-NN)、决策树(DT)、随机森林(RF)、自适应提升(AdaBoost)、梯度提升机(GBM)和极端梯度提升(XGBoost),通过47个临床参数获得预测信息:在预测卵巢癌复发方面,机器学习算法优于传统的逻辑回归分析。在这项研究中,XGBoost 在预测卵巢癌复发方面表现最佳,准确率达到 0.95。此外,新辅助化疗、单核细胞比率(MONO%)、血细胞比容(HCT)、前白蛋白(PAB)、天冬氨酸氨基转移酶(AST)和碳水化合物抗原125(CA125)是预测卵巢癌复发最重要的生物标志物:机器学习技术可以更准确地评估卵巢癌的复发情况,从而帮助临床医生做出决策,并制定个性化的治疗策略。
{"title":"Predicting the Recurrence of Ovarian Cancer Based on Machine Learning.","authors":"Lining Zhou, Hong Hong, Fuying Chu, Xiang Chen, Chenlu Wang","doi":"10.2147/CMAR.S482837","DOIUrl":"https://doi.org/10.2147/CMAR.S482837","url":null,"abstract":"<p><strong>Background: </strong>Recurrence is the main factor for poor prognosis in ovarian cancer, but few prognostic biomarkers were reported. In this study, we used machine learning methods based on multiple biomarkers to develop a specific prediction model for the recurrence of ovarian cancer.</p><p><strong>Methods: </strong>A total of 277 ovarian cancer patients were enrolled in this study and randomly classified into training and testing cohorts. The prediction information was obtained through 47 clinical parameters using six supervised clustering machine learning algorithms, including K-Nearest Neighbor (K-NN), Decision Tree (DT), Random Forest (RF), Adaptive Boosting (AdaBoost), Gradient Boosting Machine (GBM), and Extreme Gradient Boosting (XGBoost).</p><p><strong>Results: </strong>In predicting the recurrence of ovarian cancer, machine learning algorithm was superior to conventional logistic regression analysis. In this study, XGBoost showed the best performance in predicting the recurrence of ovarian cancer, with an accuracy of 0.95. In addition, neoadjuvant chemotherapy, Monocyte ratio (MONO%), Hematocrit (HCT), Prealbumin (PAB), Aspartate aminotransferase (AST), and carbohydrate antigen 125 (CA125) are the most important biomarkers to predict the recurrence of ovarian cancer.</p><p><strong>Conclusion: </strong>The machine learning techniques can achieve a more accurate assessment of the recurrence of ovarian cancer, which can help clinicians make decisions, and develop personalized treatment strategies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1375-1387"},"PeriodicalIF":2.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Efficacy of Microwave Ablation Combined with Percutaneous Osteoplasty in the Treatment of Flat Bone Metastases. 微波消融联合经皮骨成形术治疗扁平骨转移瘤的临床疗效。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-05 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S482477
Zhipeng Lin, Xiaolong Hu, Dabei Huang, Xugong Zou, Yuan Chen, Xiaoqun Li, Jian Zhang

Purpose: Evaluating the clinical efficacy and safety of microwave ablation combined with percutaneous osteoplasty (MWA + PO group) versus percutaneous osteoplasty (PO group) for the treatment of flat bone metastases.

Methods: Patients with flat bone metastases and intractable pain who underwent PO and/or MWA from January 2016 to January 2023 in our hospital were included, with 36 cases in the MWA+PO group and 21 cases in the PO group. Changes in the visual analog scale (VAS), Oswestry Disability Index (ODI), and quality of life assessment scale(QOL) were evaluated regularly. Postoperative complications and target lesion tumor treatment responses were also observed.

Results: The VAS and ODI in both the MWA+PO group and the PO group significantly decreased at 1 week, 1 month, and 3 months postoperatively, The VAS and ODI in the MWA+PO group were lower than those in the PO group postoperatively. The QOL in both the MWA+PO group and the PO group significantly increased at 1 week, 1 month, and 3 months postoperatively, with the QOL in the MWA+PO group being higher than that in the PO group postoperatively. According to the mRECIST criteria (target lesion tumor treatment response), the ORR in the MWA+PO group and PO group was 52.8% and 9.5%, respectively, while the DCR was 94.4% and 57.1%, respectively (P <0.001 and<0.001). Different degrees of bone cement extravasation were observed in both the PO group (38.1%) and MWA+PO group(19.4%)(χ²=2.38, P=0.12), but none of the patients developed clinical symptoms related to bone cement extravasation. The average cost of surgery was ¥10,480.43 higher in the MWA+PO group than in the PO group.

Conclusion: The MWA+PO treatment is more effective in relieving patients' local pain, improving local dysfunction, and enhancing quality of life, and can effectively improve target lesion tumor ORR and DCR, but it is also more costly.

目的:评价微波消融联合经皮骨膜成形术(MWA+PO组)与经皮骨膜成形术(PO组)治疗扁平骨转移瘤的临床疗效和安全性:纳入2016年1月至2023年1月在我院接受PO和/或MWA治疗的扁平骨转移瘤和难治性疼痛患者,其中MWA+PO组36例,PO组21例。定期评估视觉模拟量表(VAS)、Oswestry残疾指数(ODI)和生活质量评估量表(QOL)的变化。此外,还观察了术后并发症和靶病灶肿瘤治疗反应:术后1周、1个月和3个月,MWA+PO组和PO组的VAS和ODI均明显下降,MWA+PO组的VAS和ODI均低于PO组。术后 1 周、1 个月和 3 个月时,MWA+PO 组和 PO 组的 QOL 均明显增加,其中 MWA+PO 组术后的 QOL 高于 PO 组。根据mRECIST标准(靶病灶肿瘤治疗反应),MWA+PO组和PO组的ORR分别为52.8%和9.5%,DCR分别为94.4%和57.1%(P 结论:MWA+PO组和PO组的ORR和DCR均高于MWA+PO组:MWA+PO治疗在缓解患者局部疼痛、改善局部功能障碍、提高生活质量方面更有效,能有效提高靶病灶肿瘤ORR和DCR,但费用也更高。
{"title":"Clinical Efficacy of Microwave Ablation Combined with Percutaneous Osteoplasty in the Treatment of Flat Bone Metastases.","authors":"Zhipeng Lin, Xiaolong Hu, Dabei Huang, Xugong Zou, Yuan Chen, Xiaoqun Li, Jian Zhang","doi":"10.2147/CMAR.S482477","DOIUrl":"10.2147/CMAR.S482477","url":null,"abstract":"<p><strong>Purpose: </strong>Evaluating the clinical efficacy and safety of microwave ablation combined with percutaneous osteoplasty (MWA + PO group) versus percutaneous osteoplasty (PO group) for the treatment of flat bone metastases.</p><p><strong>Methods: </strong>Patients with flat bone metastases and intractable pain who underwent PO and/or MWA from January 2016 to January 2023 in our hospital were included, with 36 cases in the MWA+PO group and 21 cases in the PO group. Changes in the visual analog scale (VAS), Oswestry Disability Index (ODI), and quality of life assessment scale(QOL) were evaluated regularly. Postoperative complications and target lesion tumor treatment responses were also observed.</p><p><strong>Results: </strong>The VAS and ODI in both the MWA+PO group and the PO group significantly decreased at 1 week, 1 month, and 3 months postoperatively, The VAS and ODI in the MWA+PO group were lower than those in the PO group postoperatively. The QOL in both the MWA+PO group and the PO group significantly increased at 1 week, 1 month, and 3 months postoperatively, with the QOL in the MWA+PO group being higher than that in the PO group postoperatively. According to the mRECIST criteria (target lesion tumor treatment response), the ORR in the MWA+PO group and PO group was 52.8% and 9.5%, respectively, while the DCR was 94.4% and 57.1%, respectively (P <0.001 and<0.001). Different degrees of bone cement extravasation were observed in both the PO group (38.1%) and MWA+PO group(19.4%)(χ²=2.38, P=0.12), but none of the patients developed clinical symptoms related to bone cement extravasation. The average cost of surgery was ¥10,480.43 higher in the MWA+PO group than in the PO group.</p><p><strong>Conclusion: </strong>The MWA+PO treatment is more effective in relieving patients' local pain, improving local dysfunction, and enhancing quality of life, and can effectively improve target lesion tumor ORR and DCR, but it is also more costly.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1363-1373"},"PeriodicalIF":2.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awareness and Knowledge of Tobacco Use and Its Relation to Oral Cancer Among Patients Visiting Stomatology Teaching Hospital. 口腔医学教学医院就诊患者对吸烟及其与口腔癌关系的认识和了解。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S479933
Fariha Kamal, Elaha Somaya Ghafary, Mohammad Hassan Hamrah, Ghulam Sarwar Khalid, Mohammad Hussain Hamrah, Zaheruddin Hasam, Neghat Ghafoory

Background: Oral cancer (OC) is a major global health issue, with tobacco use being one of the most significant preventable risk factors. Despite its strong association with OC, public awareness about the harmful effects of tobacco remains limited. This study aims to evaluate the awareness and knowledge of tobacco use related to oral cancer among patients referred to the Stomatology Teaching Hospital.

Methods: A cross-sectional survey was conducted at the Stomatology Teaching Hospital of Kabul University of Medical Sciences (KUMS) between January 1 and July 30, 2023. Using a convenience sampling method, the study included 435 patients aged 15 to 76 years. Logistic regression analysis was employed to determine factors associated with tobacco use, and the data were analyzed using SPSS version 26.0.

Results: Participants were divided into two groups: tobacco users and non-tobacco users. Most of them were young (18 to 30 years old) with a significant difference in oral cancer knowledge between the two groups (p < 0.001). Cigarettes were the most common tobacco type among users (62.1%), which was also statistically significant (p < 0.001). Tobacco users were 3.04 times more likely to have knowledge about oral cancer (OR: 3.04, p < 0.001, 95% CI: 1.93-4.80), indicating a significant association.

Conclusion: The study reveals a general lack of awareness about oral cancer in our study population, particularly regarding specific risk factors. To improve awareness, it is essential for both public awareness campaigns and dentists to play a more active role in educating the public about oral cancer.

背景:口腔癌(OC)是一个重大的全球性健康问题,而吸烟是最重要的可预防风险因素之一。尽管烟草与口腔癌密切相关,但公众对烟草危害的认识仍然有限。本研究旨在评估口腔医学教学医院转诊患者对与口腔癌相关的烟草使用的认识和知识:方法:2023 年 1 月 1 日至 7 月 30 日期间,在喀布尔医科大学(KUMS)口腔教学医院进行了一项横断面调查。研究采用方便抽样法,纳入了 435 名 15 至 76 岁的患者。采用逻辑回归分析法确定与吸烟相关的因素,并使用 SPSS 26.0 版对数据进行分析:参与者分为两组:吸烟者和非吸烟者。他们大多是年轻人(18 至 30 岁),两组在口腔癌知识方面存在显著差异(P < 0.001)。吸烟者中最常见的烟草类型是香烟(62.1%),这也具有统计学意义(p < 0.001)。吸烟者了解口腔癌知识的可能性是吸烟者的 3.04 倍(OR:3.04,p < 0.001,95% CI:1.93-4.80),这表明两者之间存在显著关联:研究显示,我们的研究对象普遍缺乏对口腔癌的认识,尤其是对特定风险因素的认识。为了提高人们的认识,公众宣传活动和牙医都必须在教育公众了解口腔癌方面发挥更积极的作用。
{"title":"Awareness and Knowledge of Tobacco Use and Its Relation to Oral Cancer Among Patients Visiting Stomatology Teaching Hospital.","authors":"Fariha Kamal, Elaha Somaya Ghafary, Mohammad Hassan Hamrah, Ghulam Sarwar Khalid, Mohammad Hussain Hamrah, Zaheruddin Hasam, Neghat Ghafoory","doi":"10.2147/CMAR.S479933","DOIUrl":"https://doi.org/10.2147/CMAR.S479933","url":null,"abstract":"<p><strong>Background: </strong>Oral cancer (OC) is a major global health issue, with tobacco use being one of the most significant preventable risk factors. Despite its strong association with OC, public awareness about the harmful effects of tobacco remains limited. This study aims to evaluate the awareness and knowledge of tobacco use related to oral cancer among patients referred to the Stomatology Teaching Hospital.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted at the Stomatology Teaching Hospital of Kabul University of Medical Sciences (KUMS) between January 1 and July 30, 2023. Using a convenience sampling method, the study included 435 patients aged 15 to 76 years. Logistic regression analysis was employed to determine factors associated with tobacco use, and the data were analyzed using SPSS version 26.0.</p><p><strong>Results: </strong>Participants were divided into two groups: tobacco users and non-tobacco users. Most of them were young (18 to 30 years old) with a significant difference in oral cancer knowledge between the two groups (p < 0.001). Cigarettes were the most common tobacco type among users (62.1%), which was also statistically significant (p < 0.001). Tobacco users were 3.04 times more likely to have knowledge about oral cancer (OR: 3.04, p < 0.001, 95% CI: 1.93-4.80), indicating a significant association.</p><p><strong>Conclusion: </strong>The study reveals a general lack of awareness about oral cancer in our study population, particularly regarding specific risk factors. To improve awareness, it is essential for both public awareness campaigns and dentists to play a more active role in educating the public about oral cancer.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1345-1352"},"PeriodicalIF":2.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNAs as Biomarkers of Brain Tumor. 作为脑肿瘤生物标志物的微小 RNA。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S484158
Wojciech Jelski, Barbara Mroczko

Brain tumors have been deadly cancers for years, and in most cases they are difficult to diagnose in their early stages. For this reason, researchers need to develop low-cost, sensitive methods for examining cancer biomarkers. Such biomarkers include microRNA. MicroRNA expression in various body fluids shows a high correlation with cancer. A number of studies have demonstrated changes in microRNA expression in cerebrospinal fluid and blood samples from patients with brain tumors. New biomarkers such as microRNAs may help diagnose brain tumors at the very beginning of the disease, enabling early treatment and increasing the chances of survival. This review describes the diagnostic role of microRNAs and the prospects for their use as biomarkers in patients with brain tumors.

多年来,脑肿瘤一直是致命的癌症,在大多数情况下,它们很难在早期阶段被诊断出来。因此,研究人员需要开发低成本、灵敏的癌症生物标志物检测方法。这类生物标志物包括 microRNA。各种体液中的 microRNA 表达与癌症有很高的相关性。多项研究表明,脑肿瘤患者脑脊液和血液样本中的 microRNA 表达发生了变化。新的生物标志物(如 microRNA)可能有助于在疾病初期诊断脑肿瘤,从而实现早期治疗并增加生存机会。这篇综述介绍了微RNA的诊断作用及其在脑肿瘤患者中用作生物标记物的前景。
{"title":"MicroRNAs as Biomarkers of Brain Tumor.","authors":"Wojciech Jelski, Barbara Mroczko","doi":"10.2147/CMAR.S484158","DOIUrl":"https://doi.org/10.2147/CMAR.S484158","url":null,"abstract":"<p><p>Brain tumors have been deadly cancers for years, and in most cases they are difficult to diagnose in their early stages. For this reason, researchers need to develop low-cost, sensitive methods for examining cancer biomarkers. Such biomarkers include microRNA. MicroRNA expression in various body fluids shows a high correlation with cancer. A number of studies have demonstrated changes in microRNA expression in cerebrospinal fluid and blood samples from patients with brain tumors. New biomarkers such as microRNAs may help diagnose brain tumors at the very beginning of the disease, enabling early treatment and increasing the chances of survival. This review describes the diagnostic role of microRNAs and the prospects for their use as biomarkers in patients with brain tumors.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1353-1361"},"PeriodicalIF":2.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Glutamine-Enhanced Parenteral Nutrition on Postoperative Outcomes in Colorectal Cancer Patients. 谷氨酰胺强化肠外营养对结直肠癌患者术后疗效的影响
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-02 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S476648
Yong Huang, Chunmei Yin, Jue Wang, Maijian Wang, Xingbin Zheng, Ming Xie, Jiwei Wang

Purpose: This study investigated the effects of parenteral glutamine (Gln) supplement immunonutrition versus conventional nutritional support on postoperative Clavien-Dindo classification complications and recovery, perioperative nutritional status, and immune, inflammation, and safety indicators in patients with colorectal cancer (CRC).

Patients and methods: Clinical data were collected for a retrospective cohort study of 178 patients (58 and 120 patients in the observation and control groups, respectively) who underwent radical resection of CRC from January 2019 to December 2021. The incidence of postoperative complications was calculated. Postoperative recovery, nutritional indicators, inflammatory factors indicator, and the safety indicators before operation and at 1, 3, and 7 days after operation were compared. SPSS 29.0 statistical software was used for statistical analysis.

Results: The incidence of postoperative overall complications in the control group and the observation group was 22.50% (27/120) and 17.24% (10/58), respectively, and there was no significant difference between the two groups (P=0.42). The incidence of postoperative complications of Clavien-Dindo grade ≥III in the control group and the observation group was 14.17% (17/120) and 3.45% (2/58), respectively, and the difference between the two groups was statistically significant (P=0.03). Secondary outcomes (first exhaust, defecation, and liquid diet intake times) were significantly recovered earlier in the observation group than those in the control group (P<0.05), while the postoperative hospital stay was significantly shorter(P=0.04). The perioperative nutritional status did not significantly differ between the groups before and after surgery(P>0.05), although significant differences were observed in several inflammatory and safety indicators(P<0.05).

Conclusion: Unlike conventional nutritional support, postoperative parenteral Gln supplementation reduced the incidence of postoperative Clavien-Dindo complications grade ≥III in patients with CRC while increasing intestinal and immune functions, decreasing inflammation, and reducing the length of hospital stay.

目的:本研究调查了肠外谷氨酰胺(Gln)补充免疫营养与常规营养支持对结直肠癌(CRC)患者术后Clavien-Dindo分类并发症和恢复、围手术期营养状况以及免疫、炎症和安全指标的影响:一项回顾性队列研究收集了2019年1月至2021年12月期间接受CRC根治性切除术的178名患者(观察组和对照组分别有58名和120名患者)的临床数据。计算了术后并发症的发生率。比较术后恢复情况、营养指标、炎症因子指标以及术前和术后1、3、7天的安全性指标。统计分析采用 SPSS 29.0 统计软件:对照组和观察组的术后总并发症发生率分别为 22.50%(27/120)和 17.24%(10/58),两组差异无显著性(P=0.42)。对照组和观察组术后 Clavien-Dindo ≥III 级并发症的发生率分别为 14.17%(17/120)和 3.45%(2/58),两组间差异有统计学意义(P=0.03)。观察组的次要结果(首次排气、排便和流质饮食摄入时间)明显早于对照组(PP=0.04)。观察组和对照组在手术前后的围手术期营养状况没有明显差异(P>0.05),但在一些炎症和安全指标上有显著差异(PC结论:与传统的营养支持不同,术后家长营养支持是一种新的营养支持方式:与传统的营养支持不同,术后肠外补充 Gln 可降低 CRC 患者术后 Clavien-Dindo 并发症≥III 级的发生率,同时提高肠道和免疫功能,减少炎症,缩短住院时间。
{"title":"Impact of Glutamine-Enhanced Parenteral Nutrition on Postoperative Outcomes in Colorectal Cancer Patients.","authors":"Yong Huang, Chunmei Yin, Jue Wang, Maijian Wang, Xingbin Zheng, Ming Xie, Jiwei Wang","doi":"10.2147/CMAR.S476648","DOIUrl":"10.2147/CMAR.S476648","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigated the effects of parenteral glutamine (Gln) supplement immunonutrition versus conventional nutritional support on postoperative Clavien-Dindo classification complications and recovery, perioperative nutritional status, and immune, inflammation, and safety indicators in patients with colorectal cancer (CRC).</p><p><strong>Patients and methods: </strong>Clinical data were collected for a retrospective cohort study of 178 patients (58 and 120 patients in the observation and control groups, respectively) who underwent radical resection of CRC from January 2019 to December 2021. The incidence of postoperative complications was calculated. Postoperative recovery, nutritional indicators, inflammatory factors indicator, and the safety indicators before operation and at 1, 3, and 7 days after operation were compared. SPSS 29.0 statistical software was used for statistical analysis.</p><p><strong>Results: </strong>The incidence of postoperative overall complications in the control group and the observation group was 22.50% (27/120) and 17.24% (10/58), respectively, and there was no significant difference between the two groups (<i>P</i>=0.42). The incidence of postoperative complications of Clavien-Dindo grade ≥III in the control group and the observation group was 14.17% (17/120) and 3.45% (2/58), respectively, and the difference between the two groups was statistically significant (<i>P</i>=0.03). Secondary outcomes (first exhaust, defecation, and liquid diet intake times) were significantly recovered earlier in the observation group than those in the control group (<i>P</i><0.05), while the postoperative hospital stay was significantly shorter(<i>P</i>=0.04). The perioperative nutritional status did not significantly differ between the groups before and after surgery(<i>P</i>>0.05), although significant differences were observed in several inflammatory and safety indicators(<i>P</i><0.05).</p><p><strong>Conclusion: </strong>Unlike conventional nutritional support, postoperative parenteral Gln supplementation reduced the incidence of postoperative Clavien-Dindo complications grade ≥III in patients with CRC while increasing intestinal and immune functions, decreasing inflammation, and reducing the length of hospital stay.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1329-1344"},"PeriodicalIF":2.5,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer. 全面分析乳腺癌基因 1 (BRCA-1) 在膀胱癌中的意义。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S467817
Xinyu Zhang, Xiaoxuan Tao, Yuxin Zhou, Guangyue Shi, Tianjiao Wang

Background: Bladder carcinoma (BLCA) is characterized by high morbidity, mortality, and treatment costs. Breast cancer gene 1 (BRCA1), a tumor suppressor gene, inhibits the development of malignant tumors. However, research on the significance of BRCA1 in BLCA is limited. This study aims to explore the importance of BRCA1 in BLCA using bioinformatic methods and immunohistochemistry.

Methods: Gene expression, clinical, and survival data were collected from the TCGA databases through the UCSC Xena platform (http://xena.ucsc.edu/). The TPM data from the TCGA and GETEx databases were integrated using the GEPIA database (http://GEPIA.cancer-pku.cn). The study then explored the differential expression, survival prognosis, functional enrichment, and immune cell infiltration analyses of BRCA1 in BLCA. A PPI network of BRCA1 was constructed using the STRING database, and a BRCA1-associated gene-gene interaction network was generated using the GeneMANIA database. Immunohistochemistry (IHC) assays were performed to verify the expression levels of BRCA1 in bladder tumour tissues and adjacent normal tissues.

Results: BRCA1 is associated with BLCA. Differential analysis indicated that BRCA1 acts as a risk factor for BLCA but does not show significant expression differences across genders, stages, tumor stages, lymph node stages, or metastasis stages. Additionally, staging was based on the eighth edition of the American Joint Committee on Cancer (AJCC) for BLCA. Co-expression network and Gene Set Enrichment Analysis (GESA) confirmed that BRCA1 is involved in various BLCA pathways. Furthermore, BRCA1 expression was also linked to immune cell infiltration. However, survival prognosis analysis revealed no significant correlation between the prognosis of BLCA and BRCA1.

Conclusion: We demonstrated that BRCA1 is a prospective predicted and immunological biomarker in BLCA, offering new avenues for potential therapies.

背景:膀胱癌(BLCA)的特点是发病率高、死亡率高、治疗费用高。乳腺癌基因 1(BRCA1)是一种肿瘤抑制基因,可抑制恶性肿瘤的发展。然而,有关 BRCA1 在 BLCA 中重要性的研究还很有限。本研究旨在利用生物信息学方法和免疫组化技术探讨 BRCA1 在 BLCA 中的重要性:方法:通过 UCSC Xena 平台(http://xena.ucsc.edu/)从 TCGA 数据库中收集基因表达、临床和生存数据。利用 GEPIA 数据库(http://GEPIA.cancer-pku.cn)整合了来自 TCGA 和 GETEx 数据库的 TPM 数据。研究随后探讨了 BLCA 中 BRCA1 的差异表达、生存预后、功能富集和免疫细胞浸润分析。利用 STRING 数据库构建了 BRCA1 的 PPI 网络,并利用 GeneMANIA 数据库生成了 BRCA1 相关基因-基因相互作用网络。免疫组化(IHC)检测验证了 BRCA1 在膀胱肿瘤组织和邻近正常组织中的表达水平:结果:BRCA1 与 BLCA 相关。差异分析表明,BRCA1 是膀胱癌的一个危险因素,但在不同性别、分期、肿瘤分期、淋巴结分期或转移分期中,BRCA1 的表达并无明显差异。此外,BLCA 的分期是根据美国癌症联合委员会(AJCC)第八版进行的。共表达网络和基因组富集分析(GESA)证实 BRCA1 参与了 BLCA 的各种通路。此外,BRCA1 的表达还与免疫细胞浸润有关。然而,生存预后分析表明,BLCA 的预后与 BRCA1 之间无明显相关性:我们证明了 BRCA1 是 BLCA 的前瞻性预测和免疫生物标志物,为潜在疗法提供了新途径。
{"title":"Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer.","authors":"Xinyu Zhang, Xiaoxuan Tao, Yuxin Zhou, Guangyue Shi, Tianjiao Wang","doi":"10.2147/CMAR.S467817","DOIUrl":"10.2147/CMAR.S467817","url":null,"abstract":"<p><strong>Background: </strong>Bladder carcinoma (BLCA) is characterized by high morbidity, mortality, and treatment costs. Breast cancer gene 1 (BRCA1), a tumor suppressor gene, inhibits the development of malignant tumors. However, research on the significance of BRCA1 in BLCA is limited. This study aims to explore the importance of BRCA1 in BLCA using bioinformatic methods and immunohistochemistry.</p><p><strong>Methods: </strong>Gene expression, clinical, and survival data were collected from the TCGA databases through the UCSC Xena platform (http://xena.ucsc.edu/). The TPM data from the TCGA and GETEx databases were integrated using the GEPIA database (http://GEPIA.cancer-pku.cn). The study then explored the differential expression, survival prognosis, functional enrichment, and immune cell infiltration analyses of BRCA1 in BLCA. A PPI network of BRCA1 was constructed using the STRING database, and a BRCA1-associated gene-gene interaction network was generated using the GeneMANIA database. Immunohistochemistry (IHC) assays were performed to verify the expression levels of BRCA1 in bladder tumour tissues and adjacent normal tissues.</p><p><strong>Results: </strong>BRCA1 is associated with BLCA. Differential analysis indicated that BRCA1 acts as a risk factor for BLCA but does not show significant expression differences across genders, stages, tumor stages, lymph node stages, or metastasis stages. Additionally, staging was based on the eighth edition of the American Joint Committee on Cancer (AJCC) for BLCA. Co-expression network and Gene Set Enrichment Analysis (GESA) confirmed that BRCA1 is involved in various BLCA pathways. Furthermore, BRCA1 expression was also linked to immune cell infiltration. However, survival prognosis analysis revealed no significant correlation between the prognosis of BLCA and BRCA1.</p><p><strong>Conclusion: </strong>We demonstrated that BRCA1 is a prospective predicted and immunological biomarker in BLCA, offering new avenues for potential therapies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1305-1319"},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Study of Inflammatory Markers in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy. 接受调强放射治疗的鼻咽癌患者炎症标志物的预后研究
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S481142
Linbo Tang, Xinjing Li, Yongbin Wang, Yuanhe Tong

Purpose: Inflammatory markers in the blood have been linked to tumor prognosis, but their specific prognostic significance in nasopharyngeal carcinoma (NPC) patients undergoing intensity-modulated radiotherapy (IMRT) is not well established. This study aims to evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in this patient population.

Patients and methods: A total of 406 non-metastatic NPC patients were included in the study. NLR, PLR, and LMR were stratified according to their average values. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Cox multivariate regression analysis was performed to evaluate the associations of NLR, PLR, and LMR with PFS and OS.

Results: Patients with NLR > 2.78 had worse PFS (P = 0.008) and OS (P < 0.001); PLR > 162.48 was related to lower PFS (P = 0.018) but not OS (P = 0.29); LMR > 5.05 showed no significant difference in PFS and OS compared to LMR ≤ 5.05 (P values were 0.13 and 0.94, respectively). Multivariate analysis indicated that NLR was an independent prognostic factor for PFS (HR, 1.674; 95% CI, 1.006-2.784; P = 0.047) and OS (HR, 4.143; 95% CI, 2.111-8.129; P = 0.000), while PLR and LMR did not demonstrate significant associations with PFS and OS.

Conclusion: This study identifies NLR as a novel and independent prognostic indicator for NPC patients receiving IMRT, offering valuable insights that could inform future clinical decision-making. In contrast, PLR and LMR did not demonstrate significant prognostic value in this context.

目的:血液中的炎症标志物与肿瘤预后有关,但它们在接受调强放射治疗(IMRT)的鼻咽癌(NPC)患者中的具体预后意义尚未明确。本研究旨在评估中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和淋巴细胞与单核细胞比值(LMR)在该患者群体中的预后价值:研究共纳入了 406 名非转移性鼻咽癌患者。根据 NLR、PLR 和 LMR 的平均值进行分层。采用 Kaplan-Meier 法估算无进展生存期(PFS)和总生存期(OS)。对NLR、PLR和LMR与PFS和OS的关系进行了Cox多变量回归分析:结果:NLR > 2.78的患者PFS(P = 0.008)和OS(P < 0.001)较差;PLR > 162.48与较低的PFS(P = 0.018)有关,但与OS(P = 0.29)无关;LMR > 5.05与LMR ≤ 5.05相比,PFS和OS无显著差异(P值分别为0.13和0.94)。多变量分析表明,NLR是PFS(HR,1.674;95% CI,1.006-2.784;P = 0.047)和OS(HR,4.143;95% CI,2.111-8.129;P = 0.000)的独立预后因素,而PLR和LMR与PFS和OS无明显关联:本研究发现,NLR是接受IMRT治疗的鼻咽癌患者的一个新的独立预后指标,为未来的临床决策提供了有价值的信息。相比之下,PLR 和 LMR 在这种情况下并未显示出显著的预后价值。
{"title":"Prognostic Study of Inflammatory Markers in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy.","authors":"Linbo Tang, Xinjing Li, Yongbin Wang, Yuanhe Tong","doi":"10.2147/CMAR.S481142","DOIUrl":"10.2147/CMAR.S481142","url":null,"abstract":"<p><strong>Purpose: </strong>Inflammatory markers in the blood have been linked to tumor prognosis, but their specific prognostic significance in nasopharyngeal carcinoma (NPC) patients undergoing intensity-modulated radiotherapy (IMRT) is not well established. This study aims to evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in this patient population.</p><p><strong>Patients and methods: </strong>A total of 406 non-metastatic NPC patients were included in the study. NLR, PLR, and LMR were stratified according to their average values. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Cox multivariate regression analysis was performed to evaluate the associations of NLR, PLR, and LMR with PFS and OS.</p><p><strong>Results: </strong>Patients with NLR > 2.78 had worse PFS (P = 0.008) and OS (P < 0.001); PLR > 162.48 was related to lower PFS (P = 0.018) but not OS (P = 0.29); LMR > 5.05 showed no significant difference in PFS and OS compared to LMR ≤ 5.05 (P values were 0.13 and 0.94, respectively). Multivariate analysis indicated that NLR was an independent prognostic factor for PFS (HR, 1.674; 95% CI, 1.006-2.784; P = 0.047) and OS (HR, 4.143; 95% CI, 2.111-8.129; P = 0.000), while PLR and LMR did not demonstrate significant associations with PFS and OS.</p><p><strong>Conclusion: </strong>This study identifies NLR as a novel and independent prognostic indicator for NPC patients receiving IMRT, offering valuable insights that could inform future clinical decision-making. In contrast, PLR and LMR did not demonstrate significant prognostic value in this context.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1321-1328"},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Influence of Sociodemographic Factors and Clinical Aspects on the Quality of Life of Surgically Treated Patients with Colorectal Cancer. 社会人口因素和临床因素对接受手术治疗的结直肠癌患者生活质量的影响
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-27 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S478179
Filip Świątkowski, Jakub Lambrinow, Tomasz Górnicki, Marta Jurga, Mariusz Chabowski

Introduction: Due to the increasing number of cases and the levels of mortality, colorectal cancer is still a major health problem. Therefore, the growing interest in the quality of life of patients and the assessment of the quality of life of patients with colorectal cancer seems to be particularly important. The aim of the study was to investigate and determine factors that have a significant impact on the QoL of patients who were diagnosed with colorectal cancer that was surgically treated in the Surgical Department of the 4th Military Clinical Hospital in Wroclaw.

Methods: 102 respondents were enrolled into the study. The QLQ-C30, QLQ-CR29 as well as an original questionnaire regarding the socioeconomic factors were used for the assessment. The information was supplemented with patients' clinical data.

Results: According to the QLQ-C30 questionnaire the average QoL of the respondents was 55%. Factors such as male gender, younger age, higher BMI, no significant weight loss, living with family, lower level of education and being professionally active have significant positive impact on QoL. In contrary, patients with more advanced and malignant cancer with tumor located in the right half of the colon had worse QoL. The particular domains of QoL influenced by these factors were also identified. Determining these factors will allow for more effective treatment, for the shortening of the hospitalization and finally for the reduction of the costs.

Conclusion: The better QoL of the patients with colorectal cancer treated surgically showed younger men, living with family and with the support from close people, professionally active, with primary level of education, and without significant weight loss, ie less than 5% of body weight in the last 6 months. Moreover, patients with cancer located in the left colon, at a lower stage, with a lower grading demonstrated a better QoL.

导言:由于患病人数和死亡率不断增加,大肠癌仍然是一个重大的健康问题。因此,人们对患者生活质量的关注与日俱增,对结直肠癌患者生活质量的评估显得尤为重要。本研究旨在调查并确定对弗罗茨瓦夫第四军事临床医院外科手术治疗的结直肠癌患者生活质量有重大影响的因素。评估使用了 QLQ-C30、QLQ-CR29 以及有关社会经济因素的原始问卷。患者的临床数据对这些信息进行了补充:根据 QLQ-C30 问卷,受访者的平均 QoL 为 55%。性别为男性、年龄较小、体重指数(BMI)较高、体重无明显减轻、与家人同住、教育程度较低和从事职业活动等因素对 QoL 有显著的积极影响。相反,肿瘤位于结肠右半部的晚期恶性肿瘤患者的 QoL 较差。此外,还确定了受这些因素影响的特定 QoL 领域。确定这些因素将有助于更有效的治疗,缩短住院时间,最终降低费用:通过手术治疗的结直肠癌患者的生活质量较好,这表明这些患者都是年轻男性,与家人生活在一起并得到亲朋好友的支持,从事职业活动,受过初等教育,体重没有明显下降,即在过去 6 个月中体重下降少于 5%。此外,癌症位于左侧结肠、分期较短、分级较低的患者的生活质量也较高。
{"title":"The Influence of Sociodemographic Factors and Clinical Aspects on the Quality of Life of Surgically Treated Patients with Colorectal Cancer.","authors":"Filip Świątkowski, Jakub Lambrinow, Tomasz Górnicki, Marta Jurga, Mariusz Chabowski","doi":"10.2147/CMAR.S478179","DOIUrl":"10.2147/CMAR.S478179","url":null,"abstract":"<p><strong>Introduction: </strong>Due to the increasing number of cases and the levels of mortality, colorectal cancer is still a major health problem. Therefore, the growing interest in the quality of life of patients and the assessment of the quality of life of patients with colorectal cancer seems to be particularly important. The aim of the study was to investigate and determine factors that have a significant impact on the QoL of patients who were diagnosed with colorectal cancer that was surgically treated in the Surgical Department of the 4th Military Clinical Hospital in Wroclaw.</p><p><strong>Methods: </strong>102 respondents were enrolled into the study. The QLQ-C30, QLQ-CR29 as well as an original questionnaire regarding the socioeconomic factors were used for the assessment. The information was supplemented with patients' clinical data.</p><p><strong>Results: </strong>According to the QLQ-C30 questionnaire the average QoL of the respondents was 55%. Factors such as male gender, younger age, higher BMI, no significant weight loss, living with family, lower level of education and being professionally active have significant positive impact on QoL. In contrary, patients with more advanced and malignant cancer with tumor located in the right half of the colon had worse QoL. The particular domains of QoL influenced by these factors were also identified. Determining these factors will allow for more effective treatment, for the shortening of the hospitalization and finally for the reduction of the costs.</p><p><strong>Conclusion: </strong>The better QoL of the patients with colorectal cancer treated surgically showed younger men, living with family and with the support from close people, professionally active, with primary level of education, and without significant weight loss, ie less than 5% of body weight in the last 6 months. Moreover, patients with cancer located in the left colon, at a lower stage, with a lower grading demonstrated a better QoL.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1293-1303"},"PeriodicalIF":2.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mixed Medullary-Papillary Thyroid Carcinoma with Mixed Lymph Node Metastases: a Case Report and Review of the Literature. 混合性髓样-乳头状甲状腺癌伴混合性淋巴结转移:病例报告与文献综述》(Medullary-Papillary Thyroid Carcinoma with Mixed Lymph Node Metastases: A Case Report and Review of the Literature)。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-24 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S464797
Yu Yang, Jingyi Zhang, Jianhua Wang

Papillary thyroid and medullary thyroid cancers are two distinct types of thyroid neoplasms. Co-occurrence of these cancers is rare, especially in mixed tumours with lymph node metastases. A 66-year-old man presented with a thyroid tumour. Thyroid ultrasonography revealed three separate nodules in the thyroid, suspected to be associated with lymph node metastasis. Although preoperative thyroid function was normal, calcitonin and carcinoembryonic antigen levels were elevated. The patient underwent a total cervical thyroidectomy with bilateral radical dissection. Histological and immunohistochemical analyses identified mixed medullary and papillary thyroid carcinoma (MMPTC) in the nodules in the left lobe of the thyroid and the isthmus. Mixed metastatic spread was observed in several lymph nodes from the neck dissection specimen. Accurate diagnosis of the rare co-occurrences of papillary and medullary thyroid carcinomas is crucial. TSH suppression can be effective for treating papillary thyroid carcinoma, whereas radical surgery is the preferred treatment for medullary thyroid carcinoma. Identifying lymph node metastasis before surgery is a key surgical strategy.

甲状腺乳头状癌和甲状腺髓样癌是两种不同类型的甲状腺肿瘤。这两种癌症很少同时发生,尤其是在有淋巴结转移的混合瘤中。一名 66 岁的男子患有甲状腺肿瘤。甲状腺超声检查发现甲状腺内有三个独立的结节,怀疑与淋巴结转移有关。虽然术前甲状腺功能正常,但降钙素和癌胚抗原水平升高。患者接受了颈部甲状腺全切除术和双侧根治性切除术。组织学和免疫组化分析发现,甲状腺左叶和甲状腺峡部的结节中存在髓样和乳头状混合型甲状腺癌(MMPTC)。在颈部切除标本的多个淋巴结中观察到混合转移扩散。准确诊断甲状腺乳头状癌和甲状腺髓样癌的罕见并发症至关重要。抑制促甲状腺激素可以有效治疗甲状腺乳头状癌,而根治性手术则是甲状腺髓样癌的首选治疗方法。手术前确定淋巴结转移是一项关键的手术策略。
{"title":"Mixed Medullary-Papillary Thyroid Carcinoma with Mixed Lymph Node Metastases: a Case Report and Review of the Literature.","authors":"Yu Yang, Jingyi Zhang, Jianhua Wang","doi":"10.2147/CMAR.S464797","DOIUrl":"https://doi.org/10.2147/CMAR.S464797","url":null,"abstract":"<p><p>Papillary thyroid and medullary thyroid cancers are two distinct types of thyroid neoplasms. Co-occurrence of these cancers is rare, especially in mixed tumours with lymph node metastases. A 66-year-old man presented with a thyroid tumour. Thyroid ultrasonography revealed three separate nodules in the thyroid, suspected to be associated with lymph node metastasis. Although preoperative thyroid function was normal, calcitonin and carcinoembryonic antigen levels were elevated. The patient underwent a total cervical thyroidectomy with bilateral radical dissection. Histological and immunohistochemical analyses identified mixed medullary and papillary thyroid carcinoma (MMPTC) in the nodules in the left lobe of the thyroid and the isthmus. Mixed metastatic spread was observed in several lymph nodes from the neck dissection specimen. Accurate diagnosis of the rare co-occurrences of papillary and medullary thyroid carcinomas is crucial. TSH suppression can be effective for treating papillary thyroid carcinoma, whereas radical surgery is the preferred treatment for medullary thyroid carcinoma. Identifying lymph node metastasis before surgery is a key surgical strategy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1285-1291"},"PeriodicalIF":2.5,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends 在 mCRPC 治疗中整合 PARP 抑制剂:当前策略和新趋势
IF 3.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-17 DOI: 10.2147/cmar.s411023
Bicky Thapa, Navonil De Sarkar, Subhajit Giri, Komal Sharma, Mingee Kim, Deepak Kilari
Abstract: Metastatic castrate-resistant prostate cancer (mCRPC) is associated with poor prognosis. DNA damage response (DDR) genes are commonly altered in mCRPC rendering them as promising therapeutic targets. Poly (ADP ribose) polymerase inhibitors (PARPi) demonstrated antitumor activity in mCRPC patients with DDR gene mutations through synthetic lethality. Multiple clinical trials with PARPi monotherapy exhibited encouraging clinical outcomes in selected patients with mCRPC. More recently, three Phase III randomized clinical trials (RCTs) combining PARPi with androgen receptor signaling inhibitors (ARSIs) demonstrated improved antitumor activity compared to ARSI monotherapy in mCRPC patients as the first-line therapy. Clinical benefit was more pronounced in patients harboring DDR alterations, specifically BRCA1/2. Interestingly, antitumor activity was also observed irrespective of DDR gene mutations, highlighting BRCAness phenotype with androgen receptor blockade resulting in synergistic activity between ARSIs and PARPi. In this review, we discuss the clinical efficacy and safety data of the combination of PARPi plus ARSI in all Phase 3 randomized controlled trials (RCTs), emphasizing strategies for patient selection and highlighting emerging trends based on clinical trial data.

Keywords: PARP inhibitors, talazoparib, ARSI, DDR genes, HRD, metastatic CRPC
摘要:转移性耐阉割前列腺癌(mCRPC)预后不良。DNA损伤应答(DDR)基因在mCRPC中普遍发生改变,使其成为有希望的治疗靶点。聚(ADP 核糖)聚合酶抑制剂(PARPi)通过合成致死率,在 DDR 基因突变的 mCRPC 患者中显示出抗肿瘤活性。使用 PARPi 单药治疗的多项临床试验显示,在选定的 mCRPC 患者中取得了令人鼓舞的临床结果。最近,三项将PARPi与雄激素受体信号转导抑制剂(ARSI)联合应用的III期随机临床试验(RCT)显示,与单用ARSI作为一线疗法相比,PARPi在mCRPC患者中的抗肿瘤活性有所提高。临床获益在DDR改变(特别是BRCA1/2)患者中更为明显。有趣的是,无论 DDR 基因突变与否,都能观察到抗肿瘤活性,这凸显了 BRCAness 表型与雄激素受体阻断导致的 ARSIs 和 PARPi 之间的协同活性。在这篇综述中,我们讨论了所有3期随机对照试验(RCT)中PARPi联合ARSI的临床疗效和安全性数据,强调了患者选择策略,并根据临床试验数据突出了新趋势:PARP抑制剂、talazoparib、ARSI、DDR基因、HRD、转移性CRPC
{"title":"Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends","authors":"Bicky Thapa, Navonil De Sarkar, Subhajit Giri, Komal Sharma, Mingee Kim, Deepak Kilari","doi":"10.2147/cmar.s411023","DOIUrl":"https://doi.org/10.2147/cmar.s411023","url":null,"abstract":"<strong>Abstract:</strong> Metastatic castrate-resistant prostate cancer (mCRPC) is associated with poor prognosis. DNA damage response (DDR) genes are commonly altered in mCRPC rendering them as promising therapeutic targets. Poly (ADP ribose) polymerase inhibitors (PARPi) demonstrated antitumor activity in mCRPC patients with DDR gene mutations through synthetic lethality. Multiple clinical trials with PARPi monotherapy exhibited encouraging clinical outcomes in selected patients with mCRPC. More recently, three Phase III randomized clinical trials (RCTs) combining PARPi with androgen receptor signaling inhibitors (ARSIs) demonstrated improved antitumor activity compared to ARSI monotherapy in mCRPC patients as the first-line therapy. Clinical benefit was more pronounced in patients harboring DDR alterations, specifically <em>BRCA1/2</em>. Interestingly, antitumor activity was also observed irrespective of DDR gene mutations, highlighting BRCAness phenotype with androgen receptor blockade resulting in synergistic activity between ARSIs and PARPi. In this review, we discuss the clinical efficacy and safety data of the combination of PARPi plus ARSI in all Phase 3 randomized controlled trials (RCTs), emphasizing strategies for patient selection and highlighting emerging trends based on clinical trial data.<br/><br/><strong>Keywords:</strong> PARP inhibitors, talazoparib, ARSI, DDR genes, HRD, metastatic CRPC<br/>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"189 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Management and Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1